**
A groundbreaking analysis published in *The Lancet* reveals that cervical cancer deaths among young women in England have plummeted to zero since the introduction of the HPV vaccine in 2008. This significant public health milestone indicates that the vaccine is saving lives, with approximately 200 deaths averted so far.
Historic Findings on Cervical Cancer Mortality
For the first time in recorded history, no cervical cancer fatalities were reported among women aged 20 to 24 during the period from 2020 to 2024. Prior to the vaccination initiative, it was estimated that around 23 deaths would have occurred within this age group. Professor Peter Sasieni, the lead researcher at Queen Mary University of London, expressed astonishment at the vaccine’s effectiveness, stating, “It’s incredible to think that a single jab can almost eliminate a particular type of cancer.”
The study further indicated that girls vaccinated at the ages of 12 or 13 now face an almost negligible risk of succumbing to cervical cancer before reaching 30. Historically, approximately 20 fatalities were recorded annually in this demographic prior to the vaccine’s introduction.
The Role of HPV in Cervical Cancer Cases
Cervical cancer remains a significant health concern, ranking as the 14th most common cancer among women in the UK, with around 3,300 new diagnoses each year. Human papillomavirus (HPV), which spreads through close skin-to-skin contact, is responsible for 99% of cervical cancer cases. While most HPV infections resolve without complications, some lead to abnormal cellular changes that can result in cancer years later.
As the vaccinated population ages, the authors of the report anticipate a continued decline in cervical cancer deaths. Cancer Research UK, which supported the research, hailed the findings as a monumental achievement but cautioned that vaccination rates in England currently lag behind recommended levels. Michelle Mitchell, the chief executive of Cancer Research UK, emphasised the vaccine’s effectiveness, stating, “We know the HPV vaccine is extremely effective at stopping cervical cancer before it starts and for the first time, these findings show it is saving lives.”
Personal Testimony: The Importance of Vaccination
Alexandra Legg, who missed the opportunity to receive the HPV vaccine when it was rolled out, was diagnosed with cervical cancer at the age of 30 just as she was preparing for her wedding. She recalls the moment she received the diagnosis as overwhelming and traumatic. “I remember hearing the words and I just couldn’t really breathe very well,” she shared.
Following treatment, which included the removal of lymph nodes, Alexandra welcomed her daughter Ivy a year later, naming her middle name Marvella—meaning “miracle.” Reflecting on her experience, she believes her situation could have been drastically different had she received the vaccine. Alexandra passionately advocates for the HPV vaccine, stating, “I’m a real advocate for this vaccine, and when Ivy is old enough, she’ll be first in the queue.”
The Road Ahead: Challenges in Vaccine Uptake
Despite the encouraging data regarding cervical cancer mortality, the challenge remains that vaccination rates have not met the World Health Organization’s target of 90%. Recent figures from the UK Health Security Agency show that only 76% of girls in England were vaccinated by age 15 for the 2024-25 period. Michelle Mitchell stressed the need for immediate action from the UK government to enhance vaccination efforts, particularly in communities with the lowest uptake.
The Department of Health and Social Care acknowledged the study’s findings as evidence of the HPV vaccination’s powerful impact. A representative stated, “We are boosting vaccine uptake so that more young people benefit from this life-saving protection,” which includes community pharmacy catch-up vaccination campaigns. Additionally, self-testing kits for HPV are being distributed to women who have not yet participated in cervical screening.
Why it Matters
The decline in cervical cancer deaths among young women marks a significant triumph in public health, demonstrating the life-saving potential of the HPV vaccine. While advancements have been made, the ongoing challenge of improving vaccination rates underscores the need for targeted efforts to ensure that all eligible individuals receive this critical protection. As we work towards the ambitious goal of eliminating cervical cancer as a public health issue by 2040, it is vital that awareness and access to vaccination remain at the forefront of health initiatives in the UK.
